# A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

> **NCT03192969** · PHASE3 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Abatacept
- **OTHER:** Placebo
- **DRUG:** Glucocorticoid Treatment

## Key facts

- **NCT ID:** NCT03192969
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-15
- **Primary completion:** 2020-06-07
- **Final completion:** 2021-11-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192969, "A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03192969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*